Pharmx Technologies Limited · ASX:PHX
Pharmx Technologies — Corum Group — H1 FY21 Earnings Presentation
27 slides from Pharmx Technologies's earnings presentation, Feb 24, 2021
Slide 1: Market Release: Corum building positive momentum
Corum Group Limited ABN 25 000 091 305 Level 3, 120 Sussex Street, Sydney NSW 2000 www.corumgroup.com.au Market Release For personal use only 24 February 2021 Corum building positive momentum Corum Group Limited (ASX:COO) (Corum) is pleased to announce its interim results for FY21. • Group revenue $
Slide 2: About Corum Group
Corum Group Limited ABN 25 000 091 305 Level 3, 120 Sussex Street, Sydney NSW 2000 www.corumgroup.com.au For personal use only About Corum Group Corum Group Limited [ASX:COO] (Corum) is an Australian company limited by shares that owns businesses in technology and software development. For more than
Slide 3: Corum Group Limited H1 FY21 Results
nal use only Corum Group Limited H1 FY21 Results 24 February 2021
Slide 4: Important Notice & Disclaimer
Important Notice & Disclaimer This presentation has been prepared by Corum Group Limited (COO or the assurance that the results, performance or achievements expressed or implied by Company or Corum). It should not be considered as an offer or invitation to the forward-looking statements contained in
Slide 5: H1 FY21 Key Highlights: Financials
H1 FY21 Key Highlights Financials nal use only • Revenue $6,642k, an increase of 33% on pcp • Heath Services $5,774k, up 43% on pcp • eCommerce $780k, down 18% on pcp • Underlying EBITDA $2.2m (1) compared to $0.1m in pcp, up 2,501% • Underlying NPAT of $1.5m (2) compared to a loss of ($0.5)m in pcp
Slide 6: H1 FY21 Key Highlights: Acquisition, Capital Raising, Corporate
H1 FY21 Key Highlights PharmX Acquisition • Acquisition of the 57% equity in PharmX that Corum did not already own • The Corum Board expect the acquisition to be earnings per share accretive in its first year nal use only Capital Raising • Corum undertook a 1 for 3 Non-Renounceable Rights issue (“Of
Slide 7: Australian Pharmacy Market
Australian Pharmacy Market Corum operates primarily within the Australian pharmacy sector as a software vendor & technology provider nal use only Australian Pharmacies2 Group Market Segment1 PBS Registered 3% 95% Private Hospitals 2% 13% 15% Public Hospitals 34% Australian Pharmacy Market Share2 38%
Slide 8: Corum Group
Corum Group Corum Group is a key enabler of Australian community pharmacy through its diversified pharmacy digital infrastructure nal use only Revenue Source • Dispense, Point of Sale and Head Office software (subscriptions under licences) FY20 Pro-forma • Typically payable quarterly in advance 18%
Slide 9: Our Pharmacy Software Solutions
Our Pharmacy Software Solutions Corum Health is a key enabler of Australian community pharmacy through it’s Dispense, Point of Sale and Head Office pharmacy digital infrastructure nal use only Solutions • Medication dispense systems are highly regulated • ePrescribing ready in a post COVID environme
Slide 10: PharmX Overview
PharmX Overview PharmX is the pre-eminent electronic ordering gateway for Australian pharmacy with a long track record of delivering the stability and reliability required by the high order volumes of pharmacies nal use only Key Pharmacy Benefits Key Supplier Benefits • Access all wholesalers • Sing
Slide 11: PharmX Opportunities
PharmX Opportunities There is a renewed strategic focus, the Corum Board believes the past 3 years of equity holder litigation have acted as a significant distraction to the strategic focus of PharmX nal use only Capital Investment Additional Services Corum will provide PharmX with capital investmen
Slide 12: eCommerce
eCommerce Corum eCommerce provides its clients a simple and efficient outsourced payment processing platform nal use only Our eCommerce Solution • Secure PCI compliant payment ReConnect oneCard gateway Secure payment solution primarily used by Real Estate agents without the need to maintain their ow
Slide 13: Financials
Financials O) Ajuo asn yeuc
Slide 14: H1 FY21 Financial Snapshot
H1 FY21 Financial Snapshot Sales Revenue ($000’s) Results1 H1 FY20 H1 FY21 ∆ PCP Revenue $5,011 $6,642 33% H2 nal use only $7,352 Health Services2 $4,056 $5,862 45% H2 $6,473 H2 H2 $5,348 H2 $4,813 eCommerce $955 $780 -18% $4,605 H1 H1 H1 $8,201 H1 H1 Expenses ($4,926) ($5,203) 6% $7,034 H1 $5,828 $
Slide 15: Underlying Result Reconciliation
Underlying Result Reconciliation NPAT H1 FY21 EBITDA H1 FY21 Underlying EBITDA $2,211 Revenue $6,642 Depreciation & Amortisation, interest and tax ($710) Expenses ($5,203) Underlying NPAT $1,501 nal use only PharmX + BAMM legal costs / restructuring / ($772) Reported EBITDA $1,439 redundancy PharmX
Slide 16: Positive Cashflow Momentum
Positive Cashflow Momentum Net cash from / (Used in) Operating Activities ($’000)1 nal use only • Operating cashflow improvement a key $559 focus for new Board • Positive H1 run rate in FY21 $191 • Cost optimisation a focus to minimise COVID-19 impact • Cashflow data excludes any PharmX contribution
Slide 17: Strategic Priorities
Strategic Priorities Revenue, Growth & Profitability • Improve sales performance in core pharmacy software nal use only • Continued focus on cost optimisation • Realise operating leverage in technology business Refocused Product Development • Corum Clear to be the lead solution suite • Streamline pr
Slide 18: FY21 Interim Summary
FY21 Interim Summary nal use only Refreshed Board & Profitability restored & Platform For Growth Healthtech Focus management with generating cash significant equity First revenue uplift since Over the past 12 months Provides investors exposure Corum has strengthened its FY16 and EBITDA Margin Corum
Slide 19: Questions
Questions UO) Ajuo asn yeuc
Slide 20: Appendix
Appendix UO) Ajuo asn yeuc
Slide 21: Corporate Overview
Corporate Overview Corum Group Limited (ASX:COO) Capital Structure Share Price 9.0cps Shares on Issue (m) 596.8 nal use only Market Capitalisation $55.49m Options / Perf Rights (m) 5.6 Enterprise Value (Cash 31/12/20) $47.87m Diluted Issued Capital (m) 602.4 Share Price Performance1 Major Shareholde
Slide 22: Board & Management
Board & Management Nick England - Chairman Nick has over 35 years of consulting and senior executive experience in Australia, the UK and Europe. Nick held senior management roles with Alliance UniChem PLC (now AB Walgreens) which operates more than 18,000 pharmacies across multiple countries. As Gro
Slide 23: Board & Management
Board & Management Jayne Shaw - Non-Executive Director Ms Shaw has significant experience in healthcare management and an experienced clinical background in nursing. Ms Shaw has acted in senior management roles in two Australian private hospitals and established an Australian and international consu
Slide 24: Profit & Loss
Profit & Loss Profit & Loss (A$000's) H1 FY19 H2 FY19 H1 FY20 H2 FY20 H1 FY21 ∆ PCP ∆ H2 FY20 Revenue $5,845 $5,385 $5,011 $5,632 $6,642 33% 18% Health $4,698 $4,315 $4,056 $4,763 $5,862 44.5% 23.1% eCommerce $1,147 $1,070 $955 $869 $780 -18.3% -10.2% Expenses nal use only Materials and consumables
Slide 25: Balance Sheet
Balance Sheet Balance Sheet (A$000's) FY20 H1 FY21 Current assets Cash and cash equivalents $2,323 $7,623 Trade and other receivables $3,826 $1,426 Inventories $64 $34 Income tax receivable $1,700 $779 nal use only Other assets $1,928 $1,904 Total $9,841 $11,766 Non-current assets Investments $2,686
Slide 26: Share Registry
Share Registry Top holders as of 22 February 2021 Rank Name Units % Units 1 LUJETA PTY LTD <MARGARET A/C> 110,573,181 18.53 nal use only 2 ARROTEX INVESTMENTS HOLDING 1 PTY LTD 60,000,000 10.05 3 NATIONAL NOMINEES LIMITED 34,583,841 5.80 4 MERSAULT PTY LTD <THE ENGLAND FAMILY S/F A/C> 26,766,667 4.4
Slide 27: Contact
nal use only Corum Group Limited Contact: Investor.Relations@corum.com.au